The Mechanism of and Preventive Therapy for Stroke in Patients with Atrial Fibrillation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Young-Hoon | - |
dc.contributor.author | Roh, Seung-Young | - |
dc.date.accessioned | 2021-09-04T00:10:59Z | - |
dc.date.available | 2021-09-04T00:10:59Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2016-05 | - |
dc.identifier.issn | 2287-6391 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/88787 | - |
dc.description.abstract | Atrial fibrillation is a major cardiac cause of stroke, and a pathogenesis involving thrombus formation in patients with atrial fibrillation is well established. A strategy for rhythm control that involves catheter ablation and anticoagulation therapy is evolving. A strategy for rhythm control that restores and maintains sinus rhythm should reduce the risk of ischemic stroke that is associated with atrial fibrillation; however, this is yet to be proven in large-scale randomized controlled trials. This paper reviews the emerging role of rhythm control therapy for atrial fibrillation to prevent stroke. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN STROKE SOC | - |
dc.subject | SPONTANEOUS ECHOCARDIOGRAPHIC CONTRAST | - |
dc.subject | ANTIARRHYTHMIC-DRUG THERAPY | - |
dc.subject | HEALTH-CARE PROFESSIONALS | - |
dc.subject | OXIDE SYNTHASE INHIBITOR | - |
dc.subject | VON-WILLEBRAND-FACTOR | - |
dc.subject | C-REACTIVE PROTEIN | - |
dc.subject | HIGH-RISK PATIENTS | - |
dc.subject | CATHETER ABLATION | - |
dc.subject | APPENDAGE MORPHOLOGY | - |
dc.subject | THROMBOEMBOLIC EVENTS | - |
dc.title | The Mechanism of and Preventive Therapy for Stroke in Patients with Atrial Fibrillation | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Young-Hoon | - |
dc.identifier.doi | 10.5853/jos.2016.00234 | - |
dc.identifier.scopusid | 2-s2.0-84973169251 | - |
dc.identifier.wosid | 000377556300002 | - |
dc.identifier.bibliographicCitation | JOURNAL OF STROKE, v.18, no.2, pp.129 - 137 | - |
dc.relation.isPartOf | JOURNAL OF STROKE | - |
dc.citation.title | JOURNAL OF STROKE | - |
dc.citation.volume | 18 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 129 | - |
dc.citation.endPage | 137 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART002111488 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Peripheral Vascular Disease | - |
dc.subject.keywordPlus | SPONTANEOUS ECHOCARDIOGRAPHIC CONTRAST | - |
dc.subject.keywordPlus | ANTIARRHYTHMIC-DRUG THERAPY | - |
dc.subject.keywordPlus | HEALTH-CARE PROFESSIONALS | - |
dc.subject.keywordPlus | OXIDE SYNTHASE INHIBITOR | - |
dc.subject.keywordPlus | VON-WILLEBRAND-FACTOR | - |
dc.subject.keywordPlus | C-REACTIVE PROTEIN | - |
dc.subject.keywordPlus | HIGH-RISK PATIENTS | - |
dc.subject.keywordPlus | CATHETER ABLATION | - |
dc.subject.keywordPlus | APPENDAGE MORPHOLOGY | - |
dc.subject.keywordPlus | THROMBOEMBOLIC EVENTS | - |
dc.subject.keywordAuthor | Atrial fibrillation | - |
dc.subject.keywordAuthor | lschemic stroke | - |
dc.subject.keywordAuthor | Thromboembolism | - |
dc.subject.keywordAuthor | Catheter ablation | - |
dc.subject.keywordAuthor | Rhythm control | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.